Cell Host Microbe 14 (5), 582590
Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status
10mg blend: BPC-157 5mg + TB-500 5mg
These shots are typically quick and easy to administer, and they can benefit individuals who have difficulty absorbing B12 from food or supplements
They include neuronal NOS (also known as nNOS, type I, NOS-1, and NOS-I), being the isoform found in neuronal tissues
Incapsula incident ID: 333000850031137365-39129557270074700
